14 Oct 2026 Avacta to Present Progression Free Survival Data on Faridoxorubicin (AVA6000) and the FOCUS-01 (AVA6103) Trial Design at the ESMO 2026 Congress Investors | Therapeutics
25 Sep 2026 The pre|CISION® Platform Wins Research and Development Achievement Award from Pharma Industry Awards UK 2026 Investors | Therapeutics
25 Sep 2026 The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer Therapeutics